[Federal Register: March 31, 2005 (Volume 70, Number 61)]
[Notices]
[Page 16506]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr31mr05-72]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Science Board to the Food and Drug Administration; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Science Board to the Food and Drug
Administration.
General Function of the Committee: The Board shall provide advice
primarily to the agency's Senior Science Advisor and, as needed, to the
Commissioner and other appropriate officials on specific complex and
technical issues as well as emerging issues within the scientific
community in industry and academia. Additionally, the Board will
provide advice to the agency on keeping pace with technical and
scientific evolutions in the fields of regulatory science, on
formulating an appropriate research agenda, and on upgrading its
scientific and research facilities to keep pace with these changes. It
will also provide the means for critical review of agency-sponsored
intramural and extramural scientific research programs
Date and Time: The meeting will be held on April 15, 2005, 8:30
a.m. to 5 p.m.
Location: Food and Drug Administration, 5630 Fishers Lane, rm.
1066, Rockville, MD 20857.
Contact Person: Jan Johannessen, Office of the Commissioner (HF-
33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD
20857, 301-827-6687, e-mail: jjohannessen@fda.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 3014512603. Please call the Information Line
for up-to-date information on this meeting.
Agenda: The Board will hear about and discuss the following topics:
(1) The agency's pre- and postmarketing safety programs for drugs and
biologics and (2) Good Manufacturing Practices for vaccines, blood, and
cell, tissue, and gene products.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by April 8, 2005.
Oral presentations from the public will be scheduled between
approximately 1:30 p.m. and 2:30 p.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before April 8, 2005,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Jan Johannessen at
least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: March 24, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External Relations.
[FR Doc. 05-6333 Filed 3-25-05; 3:51 pm]
BILLING CODE 4160-01-S